Document:

a50184012_ex108b.htm

Dyax Corp. has requested that portions of this document be accorded confidential treatment pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Exhibit 10.8(b)

CONFIDENTIAL DOCUMENT

 

AMENDMENT TO

SERVICES AGREEMENT

(Specialty Pharmacy and Hub Services)

This Amendment to the Services Agreement (this “Amendment”) is made and entered into as of February 15, 2011 (the “Amendment Effective Date”), by and between DYAX CORP. (“Dyax”) and US BIOSERVICES CORPORATION (“US Bio”).

WHEREAS, Dyax and US Bio entered into that certain Services Agreement, dated November 19, 2009 (the “Agreement”), pursuant to which US Bio is to provide services to Dyax in connection with the product Kalbitor®; and

WHEREAS, pursuant to and in accordance with Section 17.5 of the Agreement, the parties desire to amend to the Agreement to include terms and conditions relating to the distribution of Patient-Supplied Product (defined below).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.           Defined Terms.

Any capitalized terms that are used in this Amendment but not otherwise defined herein shall have the meanings ascribed to them in the Agreement.

2.           Amendments.

	
A.  

	
Additional Definition.  A new definition is hereby added to as Section 1.16 of the Agreement as follows:

	
  

	
1.16

	
“Patient-Supplied Product” shall mean Product that is shipped to a Patient’s home and then taken by a Patient to a healthcare provider treatment site to be administered by a health care provider in accordance with the requirements of the Product label.

	
B.

	
Additional Dyax Representations and Warranties.   A new paragraph is hereby added to the end of Section 13.7 of the Agreement as follows:

 

Dyax Representations and Warranties Related to Patient-Supplied Product.  Dyax hereby authorizes US Bio to ship Product to a Patient’s home in accordance with the requirements and processes set forth in the Statement of Work attached as Exhibit B-3.  In connection with such activities, Dyax hereby represents and warrants to US Bio that: [*****]

 

	
C.  

	
Additional Indemnification Obligations by Dyax.  A new paragraph is hereby added to the end of Section 14.2(b) of the Agreement as follows:

 

Indemnification by Dyax related to Patient-Supplied Product.  Dyax shall indemnify, defend, and hold harmless the US Bio Indemnitees against any Losses incurred by or imposed upon US Bio Indemnitees or any of them in connection with any claims, suits, demands, investigations, enforcement actions, or judgments (including any governmental or regulatory agency) which arise out of: (a) a breach of the Dyax Representations and Warranties Related to Patient-Supplied Product contained in the second paragraph of Section 13.7; (b) any claim arising out of the administration of Product , including without limitation, bodily injury or death to a patient and claims for off-label promotion; in each case except for those Losses for which US Bio has an obligation to indemnify Dyax pursuant to Section 14.2(a).

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission.  Asterisks denote such omission.

 

  

  

  

	
D.  

	
Additional Exhibit B-3.  A new Statement of Work outlining the requirements and processes applicable to Patient-Supplied Product shall be added as Exhibit B-3 to the Agreement pursuant to Section 8.1, and the services described in the new Statement of Work shall be included in the defined term “Services” under the Agreement.

3.           No Other Amendments.

Except as expressly amended hereby, the Agreement, as originally executed and delivered, remains in full force and effect.  It is agreed by the parties that all references to the Agreement hereafter made by them in any document or instrument delivered pursuant to or in connection with the Agreement shall be deemed to refer to the Agreement as amended hereby.

4.           Entire Agreement.

This Amendment and the Agreement embody the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersede all prior agreements and understandings relating to the subject matter.

5.           Counterparts.

 

This Amendment may be executed in multiple counterparts, each of which will be considered an original, but which together will constitute one and the same document.

 

 

	 	 
	 	Page 2 of 3

 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission.  Asterisks denote such omission.

 

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their duly authorized officers or representatives as of the Amendment Effective Date.

	
US Bioservices Corporation

	 	
Dyax Corp.

	 	 	 
	 	 	 
	
By:

	
/s/ Craig Miller

	 	
By:

	
/s/ Terese Murphy

	
Name:

	
Craig Miller

	 	
Name:

	
Terese Murphy

	
Title:

	
President

	 	
Title:

	
Associate Director, Market Access

 

 

	 	 
	 	Page 3 of 3

 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission.  Asterisks denote such omission.a50184012_ex108c.htm

Dyax Corp. has requested that portions of this document be accorded confidential treatment pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Exhibit 10.8(c)

CONFIDENTIAL DOCUMENT

 

AMENDMENT TO

SERVICES AGREEMENT

(Specialty Pharmacy and Hub Services)

This Amendment to the Services Agreement (this “Amendment”) is made and entered into as of May 31, 2011 (the “Amendment Effective Date”), by and between DYAX CORP. (“Dyax”) and US BIOSERVICES CORPORATION (“US Bio”).

WHEREAS, Dyax and US Bio entered into that certain Services Agreement, dated November 19, 2009 (the “Agreement”), pursuant to which US Bio is to provide services to Dyax in connection with the product Kalbitor® (ecallantide); and

WHEREAS, pursuant to and in accordance with Section 8.1 of the Agreement, the parties desire to add a new Statement of Work to the Agreement to cover additional services provided by US Bio as of the Amendment Effective Date in the manner and upon the terms and conditions set forth below.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.           Defined Terms.

Any capitalized terms that are used in this Amendment but not otherwise defined herein shall have the meanings ascribed to them in the Agreement.

2.           Amendments.

In accordance with Section 17.5 of the Agreement, Exhibit B-5 is hereby added to the Agreement and attached hereto.

3.           No Other Amendments.

Except as expressly amended hereby, the Agreement, as originally executed and delivered, remains in full force and effect.  It is agreed by the parties that all references to the Agreement hereafter made by them in any document or instrument delivered pursuant to or in connection with the Agreement shall be deemed to refer to the Agreement as amended hereby.

4.           Entire Agreement.

This Amendment and the Agreement embody the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersede all prior agreements and understandings relating to the subject matter.

5.           Counterparts.

This Amendment may be executed in multiple counterparts, each of which will be considered an original, but which together will constitute one and the same document.

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their duly authorized officers or representatives as of the Amendment Effective Date.

	
US Bioservices Corporation

	 	
Dyax Corp.

	 	 	 
	 	 	 
	
By:

	
/s/ Craig Miller

	 	
By:

	
/s/ Ivana Magovčević-Liebisch

	
Name:

	
Craig Miller

	 	
Name:

	
Ivana Magovčević-Liebisch

	
Title:

	
President

	 	
Title:

	
Executive Vice President Corporate Development and General Counsel

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission.  Asterisks denote such omission.

 

  

  

  

EXHIBIT B-5

Statement of Work for Kalbitor Access Expanded Copay Program

[*****]

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission.  Asterisks denote such omission.a50184012_ex1014c.htm

Exhibit 10.14(c)

THIRD AMENDMENT

TO

JOINT DEVELOPMENT AND LICENSE AGREEMENT

This THIRD AMENDMENT (the "Third Amendment"), dated as of December 26, 2011 (the "Third Amendment Date"), is entered into by and between Dyax Corp., with effective offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. ("Dyax"), and DefianteFarmacêutica S.A., with registered offices at Rua da Alfândega, n. 78, 3° andar, 9000-059, Funchal, Madeira, Portugal ("Defiante").  This Third Amendment further amends that certain Joint Development and License Agreement (the "Original Agreement"), dated effective as of June 18, 2010 (the "Effective Date"), as amended by the First Amendment to Joint Development and License Agreement (the "First Amendment”), dated December 21, 2010 (the "First Amendment Date") and the Second Amendment to Joint Development and License Agreement (the "Second Amendment"), dated May 21, 2011 (the "Second Amendment Date").  The Original Agreement, as amended by the First Amendment and the Second Amendment, is referred to herein as the "Amended Agreement."   All capitalized terms not otherwise defined in this Third Amendment shall be as defined in the Amended Agreement.

WHEREAS, under the terms of the Amended Agreement, Dyax has granted Defiante certain rights to Develop, Manufacture and Commercialize products incorporating DX-88 for the treatment of angioedemas and certain other indications; and

WHEREAS, the parties wish to amend certain terms and conditions applicable to Defiante's rights and obligations under the Amended Agreement.

NOW, THEREFORE, in consideration of the promises and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Dyax and Defiante hereby agree as follows:

	
1.

	
Exhibit A of the Amended Agreement is hereby amended to delete Taiwan, South Korea and Singapore from the Defiante Territory. Notwithstanding anything to the contrary contained in the Amended Agreement from and after the Third Amendment Date, Defiante shall have no further rights or obligations with respect to the Product in Taiwan, South Korea and Singapore, including any obligations to pay milestones, Development Cost or other compensation or reimbursement whatsoever in relation toTaiwan, South Korea and Singapore.

	
2.

	
Except as expressly provided otherwise in this Third Amendment, all provisions of the Amended Agreement remain in full force and effect without modification and all such terms are hereby ratified and confirmed.

	
3.

	
From and after the Third Amendment Date, the term "Agreement" as used in the Original Agreement shall mean the Original Agreement, as amended by the First Amendment, the Second Amendment and this Third Amendment.

	
4.

	
This Third Amendment may be executed in one or more counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.

IN WITNESS WHEREOF, Dyax and Defiante have caused this Third Amendment to be duly executed by their authorized representatives under seal, effective as of the Third Amendment Date.

 

	 	
DYAX CORP.

	 	 	 
	 	By: 	/s/ Ivana Magovcevic-Liebisch 
	 	 	
Name: Ivana Magovcevic-Liebisch

	 	 	
Title: Executive Vice President, Chief Business Officer and General Counsel

	 	 	 
	 	
DEFIANTE FARMACÊUTICA S.A.,

	 	 	 
	 	By: 	
/s/ Paulo Viegas

	 	 	

Name: Paulo Viegas

	 	 	
Title: CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}]]